Results 171 to 180 of about 286,227 (342)

Placebo Effect Sizes in Clinical Trials of Knee Osteoarthritis Using Intra‐Articular Injections of Biologic Agents

open access: yesArthritis Care &Research, EarlyView.
Objective Patients with knee osteoarthritis rely on symptomatic treatments, in which up to 75% of the pain reduction can be attributed to the placebo effect. This effect may vary based on treatment type (eg, biologics vs nonbiologic injection) and route of administration (eg, intra‐articular vs topical vs oral).
Johanna M. Borst   +5 more
wiley   +1 more source

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara   +8 more
wiley   +1 more source

Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review

open access: yesArthritis Care &Research, EarlyView.
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox   +3 more
wiley   +1 more source

Metabolic Consequences of Rheumatoid Arthritis

open access: yesArthritis Care &Research, EarlyView.
Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry   +2 more
wiley   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy